Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.

Pharmaceutical

Evotec

Craig Johnstone

Laetitia Rouxel

Cord Dohrmann

Hans-Ulrich Wolf

The Leadership Team at Evotec plays a crucial role in guiding the company's strategic direction and ensuring operational excellence across its drug discovery and development initiatives. Comprised of executives from various disciplines—including business development, scientific research, clinical operations, and finance—the team collaborates to optimize partnerships, drive innovation in drug discovery programs, and oversee the successful execution of projects across both the EVT Execute and EVT Innovate segments. Their leadership fosters a culture of collaboration and efficiency, supporting Evotec's mission to advance transformative healthcare solutions.

Leadership Team

About

Team members

Other teams at Evotec

Scientific Research Team

Business Development and Strategy Team